The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

The research service features daily updates ... the better. Boston, MA-based Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule ...

M.D. Ph.D., 50 Northern Ave, Boston, Massachusetts 02210, Chief Scientific Officer, Executive Vice President, Global Research Vertex Pharmaceuticals ... to the right location at needed exposures ...

In that report, analysts expect Vertex Pharmaceuticals to post earnings of $4.11 per share. This would mark year-over-year growth of 0.74 ... Based on our research, we believe these estimate ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), The Home Depot, Inc. (HD) and Vertex Pharmaceuticals Incorporated (VRTX), as well as a ...

Vertex Pharmaceuticals Incorporated (VRTX) stock saw a modest uptick, ending the day at $485.37 which represents a slight increase of $6.72 or 1.40% from the prior close of $478.65. The stock opened ...

On Monday, Wolfe Research adjusted its outlook on Vertex Pharmaceuticals (NASDAQ ... with the broader market's positive momentum for growth stocks. Vertex, known for its cystic fibrosis (CF ...

BMO Capital Markets managing director of biopharma equity research ... industry's growth. However, he sees opportunities outside of the GLP-1 landscape, pointing specifically to Regeneron (REGN ...